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http://dx.doi.org/10Chemotherapy-induced thrombocytopenia can lead to chemotherapy treatment delays or dose
reductions. The ability of romiplostim, a thrombopoietin (TPO)mimetic, to promote platelet re-
covery in a mouse model of multicycle chemotherapy/radiation therapy (CRT)-induced throm-
bocytopenia was examined. In humans, an inverse relationship between platelet counts and
endogenous TPO (eTPO) concentration exists. In a CRT mouse model, eTPO was not elevated
during the first 5 days after CRT treatment (the ‘‘eTPO gap’’), then increased to a peak 10 days
after each CRT treatment in an inverse relationship to platelet counts seen in humans. To bridge
the eTPO gap,mice were treatedwith 10–1,000mg/kg of romiplostim on day 0, 1, or 2 after CRT.
In some mice, the romiplostim dose was approximately divided over 3 days. Platelet recovery
occurred faster with romiplostim in most conditions tested. Romiplostim doses of $100 mg/kg
given on day 0 significantly lessened the platelet nadir. Fractionating the dose over 3 days did
not appear to confer a large advantage. These data may provide a rationale for clinical studies
of romiplostim in chemotherapy-induced thrombocytopenia. Copyright 2015 ISEH - Inter-
national Society for Experimental Hematology. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Chemotherapy-induced thrombocytopenia (CIT) is an un-
met medical need that can lead to delays or reductions in
scheduled chemotherapy treatment, which are associated
with poorer outcomes for cancer patients [1,2]. Severe
thrombocytopenia occurs in approximately 9% of chemo-
therapy cycles and can necessitate platelet transfusions
[1,2]. Recombinant thrombopoietin (TPO) reversed throm-
bocytopenia and increased survival in animal models of
CIT and chemotherapy/radiation therapy (CRT)-induced
thrombocytopenia [3–11]. Specifically, certain dose and
timing schedules were evaluated, and it was found that a
single TPO dose given close to the time of total body irra-
diation resulted in better recovery [3,6,7]. Early clinical
studies have demonstrated proof of concept for recombi-
nant TPO/TPO-receptor agonists [12–17]. However, clin-
ical studies using recombinant TPO were halted when
some patients treated with PEGylated recombinant human
megakaryocyte growth and development factor (PEG-
rHuMGDF), a truncated form of TPO, developed neutral-o: Ms. Patricia L. McElroy, Oncology Discovery
., One Amgen Center Drive, MS 15-2A, Thousand
ail: trish.mcelroy@amgen.com
 2015 ISEH - International Society for Experimental Hem
se (http://creativecommons.org/licenses/by-nc-nd/4.0/).
.1016/j.exphem.2015.02.004izing antibodies [18]. These findings led to the development
of alternative therapies, including romiplostim.
Romiplostim is a TPO-receptor agonist approved for the
treatment of thrombocytopenia in patients with chronic im-
mune thrombocytopenia. It is the first United States Food
and Drug Administration–approved member of a new class
of therapeutics called peptibodies, which are peptides conju-
gated to human Fc and resemble antibodies [19]. Since
chemotherapy-supportive treatmentsmay not be initiated un-
til the second or subsequent cycles of chemotherapy, after a
patient has been identified as being at risk for developing
thrombocytopenia, we developed a multicycle mouse model
and administered romiplostim after the first treatment cycle.
Using this model, we sought to understand the optimum dose
and timing of romiplostim administration that would pro-
mote platelet recovery. A CRT mouse model was used
because mice receiving single chemotherapy agents alone
did not develop thrombocytopenia severe enough that the ef-
fects of adding romiplostim would be easily detectable. Pre-
vious studies established that there is an inverse relationship
between endogenous TPO (eTPO) concentrations and
platelet counts in patients undergoing chemotherapy
[20,21].We hypothesized that understanding the relationshipatology. Published by Elsevier Inc. This is an open access article under the
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model of multicycle CRT could inform a rationale for pro-
phylactic romiplostim treatment.Materials and methods
Mice
Female B6D2F1 (BDF1) mice, aged 11 to 15 weeks, were used and
cared for in accordance with the Guide for the Care and Use of Lab-
oratory Animals, 8th Edition [22]. Animals were group housed at an
Association for Assessment and Accreditation of Laboratory Animal
Care International–accredited facility in sterile, ventilated microiso-
lator housing. All research protocols were approved by the Institu-
tional Animal Care and Use Committee. Animals had ad libitum
access to pelleted feed, food supplements, and water; were main-
tained on a 12:12 hour light:dark cycle; and had access to enrichment
opportunities. All animals were determined specific pathogen free.
Study design
Mice were treated with two or three cycles of CRT (experimental
designs depicted in Fig. 1). Each cycle was 28 days long. For the
first cycle, mice were injected intraperitoneally with 62.5 mg/kg
carboplatin on day 0. Four hours after carboplatin treatment, the
mice were exposed to 5 Gy total body radiation from a 137Cs
source (Gamma Cell 40 Irradiator, Atomic Energy of Canada
Ltd, Chalk River, Ontario, Canada). For cycles two and three,
the carboplatin dose was 56.25 mg/kg, and the radiation dose
was 4.5 Gy. This multicycle regimen of carboplatin plus irradia-Figure 1. Summary of study design. The days and doses of romiplostim adminis
figure appears online.)tion was adapted from work done by Hokom et al. [5], who
showed that the combination produced a profound thrombocyto-
penia; doses were modified in these studies to make repeated treat-
ment feasible. Romiplostim was administered subcutaneously 2,
24, or 48 hours following radiation, in cycle two, cycle three, or
both cycles. Romiplostim was not administered in the first cycle
to mirror the clinical situation. Untreated or saline-treated mice
served as positive controls, and CRT-treated mice not receiving ro-
miplostim served as negative controls. Blood samples were
collected by cardiac puncture immediately after euthanasia or
via the retro-orbital sinus while mice were anesthetized.
Due to the myelosuppressive nature of CRT, anemia developed
in addition to thrombocytopenia. To avoid severely compromising
individual mice by repeated blood sampling, a rotating cohort
design was used (except for experiment one, in which mice
were euthanized at each time point). There were 25 mice to a
group (except for experiment one, which had 75 mice per treat-
ment group to support terminal time points), and results are pre-
sented as averages of five mice per time point. Each mouse was
bled twice, once early in the cycle and a second time late in the
cycle, and was euthanized immediately following the second
sampling.
Analyte measurements
For the experiment comparing eTPO concentrations to platelet
counts, five mice per group were euthanized by CO2 inhalation
at each time point, and we collected blood by cardiac puncture
for complete blood counts (CBCs) and serum eTPO analy-
sis. Serum was analyzed for eTPO concentrations using thetration in seven different experiments are shown here. (Color illustration of
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apolis, MN). We analyzed CBCs using an automated blood
analyzer (Advia 2120, Siemens, Munich, Germany). For experi-
ments in which platelet response to romiplostim treatment was
monitored, mice were anesthetized with isoflurane, and blood
was collected for CBC from five mice per group per time point
via the retro-orbital sinus using a heparinized capillary tube.
Statistical analysis
An evaluation of treatment effect was made on each study day. An
analysis of variance (ANOVA) was performed on the log-
transformed platelet counts, with treatment used as a fixed effect in
the model. Each treatment group was compared with the group sub-
jected to CRT alone, and a Dunnett’s post-hoc test was employed to
account for the multiple comparisons. We used SAS version 9.1
(SAS Institute, Cary, NC) software on a Windows Vista (Microsoft,
Redmond,WA) operating system for these analyses.Additional eval-
uations of treatment effect across CRT with romiplostim-treated
groups on other blood cell types (e.g., reticulocytes) were made on
each study day using an ANOVA. Since these additional analyses
were performed on secondary endpoints, the Bonferroni post-hoc
test was performed as a more conservative method to account for
the multiple comparisons across the CRT with romiplostim-treated
groups. Graphpad Prism 5 (GraphPad Software, Inc., La Jolia, CA)
was used for the analysis of these secondary endpoints. Results are
presented as means6 standard error of the mean.Figure 2. Platelet counts demonstrated an inverse relationship with eTPO
concentrations during three cycles of CRT-induced thrombocytopenia in
mice. (A) Platelet counts in mice treated with CRT decreased in each cy-
cle. Platelets were measured in saline-treated mice only in the first cycle.
(B) Overlay of platelet counts and eTPO concentrations. Data are the
means of five mice per time point, and error bars represent the standard
error of the mean. (Color illustration of figure appears online.)Results
An inverse relationship between platelet counts and
endogenous thrombopoietin concentration was observed
during three successive cycles of chemotherapy/
radiation therapy
The relationship between platelet counts and eTPOconcentra-
tionwas examined during three cycles ofCRTinmice to ascer-
tain when eTPO concentrations were suboptimal and
administration of romiplostim might be efficacious. Mice
received eitherCRT treatment or subcutaneous saline as a con-
trol. Data from saline-treatedmicewere collected in cycle one
only. Platelet number decreased after eachCRTadministration
and gradually recovered to near-baseline levels at the end of
each cycle (Fig. 2A). After each administration of CRT,
eTPO concentration remained at a steady level for approxi-
mately 6 days, after which it began to increase until reaching
a peak on day 10 (Fig. 2B). This eTPO peak corresponded
with the nadir in platelet counts, and as platelet counts gradu-
ally recovered, eTPO also decreased to approximately base-
line concentration. Endogenous TPO concentration was
lower at the beginning of each successive CRT cycle than in
the previous cycle, and the amount of time required for platelet
counts to recover to baseline was progressively longer. These
results demonstrated an inverse relationship between platelet
number and eTPO concentration during three cycles of CRT.
Moreover, there appeared to be a window of time early after
CRT administration, before eTPO concentration increased,
duringwhich administration of romiplostimmight be effectivein promoting platelet recovery. This window was targeted for
treatment.Romiplostim administration in the second cycle of
chemotherapy/radiation therapy accelerated platelet
recovery
Following the theory that the first 5 days of a CRT cycle
constituted the ideal point for intervention, we examined
the efficacy of romiplostim in promoting platelet recovery
in the second cycle of CRT, the time at which, in a clinical
situation, the need for supportive care would have been
identified. Mice were treated in the second cycle with 10,
30, or 100 mg/kg of romiplostim on day 0, 1, or 2, and
platelet counts were measured throughout the cycle. In gen-
eral, romiplostim treatment caused a significant increase in
the rate of platelet recovery after CRT, especially at higher
doses given on day 0 or day 1 (Fig. 3). Administration
of romiplostim on day 0 and day 1 significantly lessened
the platelet nadir (sixfold decrease in nadir for day
Figure 3. Treatment with romiplostim in the second cycle accelerated platelet recovery compared with CRT alone. Mice were treated with 10, 30, or 100 mg/
kg of romiplostim on (A) day 0, (B) day 1, or (C) day 2 of the second CRT cycle. Untreated mice were included to show baseline platelet values. Mice with
CRT treatment alone were used as a negative control. The data shown are from two different experiments; panel A represents data from one experiment, and
panels B and C show the data from a separate experiment, hence the differences seen in the CRT-alone control data. Platelet counts were measured on the
indicated days (n 5 5 mice per group, per time point). Error bars represent the standard error of the mean. The symbols above the lines indicate days of
statistically significant differences between the following treatment groups and CRT alone: o 5 100 mg/kg; x 5 30 mg/kg; þ 5 10 mg/kg (p ! 0.05,
two-way ANOVA with Dunnett’s post-hoc test). (Color illustration of figure appears online.)
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tion for the 100-mg/kg-dose group). During the recovery
phase (i.e., the period of time after the platelet nadir), romi-
plostim treatment resulted in a dose-dependent increase in
mean platelet counts compared with CRT alone, reaching
statistical significance at several time points for all admin-
istration schedules tested. Taken together, these data indi-
cate that higher doses of romiplostim administered closer
to the time of CRT were most effective in preventing the
severe decrease in platelets caused by CRT and in acceler-
ating platelet recovery.
Responses to romiplostim administration in the third
cycle of chemotherapy/radiation therapy were similar to
those seen in the second cycle
We next examined whether treatment with 10, 30, or
100 mg/kg of romiplostim in both the second and third
cycles of CRT on days 0, 1, or 2 resulted in higher platelet
counts in the third cycle. Administration of romiplostim on
day 0 resulted in the greatest improvement, with all doses
administered on this day resulting in significantly increased
platelet counts at several time points compared with CRT
alone (Fig. 4A). The exception to this was on day 6, at
which point platelet counts were higher with CRT alone.Of note, the platelet nadir generally occurred later with
CRT alone as compared with CRT þ romiplostim. The
effectiveness of romiplostim appeared to be dose depen-
dent; mice treated with 100 mg/kg of romiplostim exhibited
more days of significantly higher platelet counts (compared
with CRT alone) than mice treated with lower doses.
Similar to the results in cycle two, it was observed that
day 0 administration in the second and third cycles lessened
the platelet nadir in cycle three. Romiplostim administered
on days 1 or 2 also resulted in increased platelet counts
compared with CRT alone but with fewer days of signifi-
cant difference from CRT alone than day 0 administration,
and neither day 1 nor day 2 treatment lessened the platelet
nadir compared with CRT alone (Figs. 4B and 4C).
Higher doses of romiplostim improved platelet recovery
compared with chemotherapy/radiation therapy alone
To determine if doses of romiplostim that were higher than
previously tested might further accelerate platelet recovery,
mice were treated with 100, 300, or 1,000 mg/kg of romi-
plostim on day 0 of cycle two or treated in both cycles
two and three. In both these situations, higher doses of
romiplostim resulted in improved platelet recovery
compared with CRT alone (Figs. 5A and 5B). When given
Figure 4. Treatment with romiplostim accelerated third-cycle platelet recovery compared with CRT alone. Mice were treated with 10, 30, or 100 mg/kg of
romiplostim on (A) day 0, (B) day 1, or (C) day 2 of the second and third CRT cycles. Untreated mice were included to show baseline platelet values. Mice
with CRT treatment alone were used as a negative control. The data shown are from two different experiments; panel (A) represents data from one exper-
iment, and panels (B) and (C) show the data from a separate experiment, hence the differences seen in the CRT-alone control data. Platelet counts were
measured in the third cycle (n 5 5 mice per group, per time point). Error bars represent the standard error of the mean. The symbols above the lines indicate
days of statistically significant differences between the following treatment groups and CRT alone: o 5 100 mg/kg; x 5 30 mg/kg; þ 5 10 mg/kg (p! 0.05,
two-way ANOVA with Dunnett’s post-hoc test). (Color illustration of figure appears online.)
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lower doses but was not different from 1,000 mg/kg in pro-
moting second-cycle platelet recovery.When given in cycles
two and three, increasing the dose above 100 mg/kg did not
result in significant improvement to cycle-three platelet
recovery, based on overall platelet counts as measured by
repeated measures analysis of variance (data not shown).
Dividing the dose of romiplostim over 3 consecutive
days also increased platelet counts
We tested dividing the total dose of romiplostim over several
days to examine whether platelet recovery also occurred in
this situation. Mice were treated with 30, 100, or 300 mg/kg
of romiplostim on each of days 0, 1, and 2 in cycle two or
cycles two and three and compared with the previous
responses to a single, large treatment dose. All doses tested
improved platelet recovery compared with CRT alone, with
the highest dose (300 þ 300 þ 300 mg/kg/day) offering the
greatest benefit (Figs. 5C and 5D).
Romiplostim had a protective effect on hemoglobin
values
In addition to its effects on platelet counts, romiplostim
also had some effects on other cell lineages. A positiveeffect on reticulocyte counts was observed in mice
receiving CRT and treated with romiplostim on day 0 of
cycle three (Fig. 6A). An early decrease in reticulocytes
was observed followed by increases on days 12 and 16 in
mice treated with 100 mg/kg of romiplostim. Romiplostim
treatment prevented the severe drop in hemoglobin in the
same animals, with higher doses closer to the administra-
tion of CRT generally providing greater protection
(Fig. 6B). An exception to the protective effect of romi-
plostim on hemoglobin values was observed when romi-
plostim was not administered until day 2 in the third
cycle of CRT. In this case, the romiplostim-treated groups
were not different from CRT alone until the last day of the
cycle, which may indicate that dosing was too late in this
cycle to provide benefit.
In addition to platelet counts, the effects of CRT and
romiplostim on other hematologic parameters were exam-
ined (data not shown). Monocyte counts fell to undetect-
able levels 4 days after CRT and did not begin to recover
until late in the cycle (approximately day 24). Romiplostim
treatment did not affect monocyte recovery following CRT
at any of the doses and schedules tested. Neutrophils
decreased to less than 10% of control values by day 4
post-CRT and did not begin to recover until approximately
Figure 5. Increased doses of romiplostim were effective in increasing platelet counts when given as a single dose or as a fractionated dose. Mice were treated
with 100, 300, or 1,000 mg/kg of romiplostim on day 0 of CRT (A) cycle two or (B) cycles two and three. (A, B) Untreated mice were included to show
baseline platelet values. Mice with CRT treatment alone were used as a negative control. Platelet counts were measured throughout cycles two or three,
as indicated (n 5 5 mice per group, per time point). Error bars represent the standard error of the mean. Symbols above the lines indicate days of statistically
significant differences between the following treatment groups and CRT alone: v5 1,000 mg/kg; z5 300 mg/kg; o5 100 mg/kg (p! 0.05, two-way ANOVA
with Dunnett’s post-hoc test). Mice were treated with 30, 100, or 300 mg/kg of romiplostim on days 0, 1, and 2 of CRT (C) cycle two, or cycles (D) two and
three. (C, D) Untreated mice were included to show baseline platelet values. Mice with CRT treatment alone were used as a negative control. Platelet counts
were measured throughout cycles two or three, as indicated (n 5 5 mice per group, per time point). Error bars represent the standard error of the mean.
Symbols above the lines indicate days of statistically significant differences between the following treatment groups and CRT alone: z 5 300 mg/kg;
o 5 100 mg/kg; x 5 30 mg/kg (p ! 0.05, two-way ANOVA with Dunnett’s post-hoc test). (Color illustration of figure appears online.)
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covery for some treatment regimens, although this was not
consistent. Specifically, in some experiments, neutrophil
counts were higher at some time points late in the cycle
in romiplostim-treated mice compared with mice receiving
CRT but no romiplostim. Basophils and eosinophils were
also decreased by CRT. Basophils decreased to undetect-
able levels and did not recover by the end of the cycle.
Eosinophils decreased to between 5% and 20% of normal,
stayed suppressed for the majority of the cycle, and
partially recovered to between 35% and 69% of normal
by the end of the cycle. These parameters were generally
unaffected by romiplostim treatment. Chemotherapy/
radiation therapy decreased lymphocyte counts to approxi-
mately 1% of baseline by day 2 post-CRT. They remained
depressed throughout the cycle and were unaffected by
romiplostim.Discussion
Chemotherapy-induced thrombocytopenia can lead to
chemotherapy treatment delays or dose reductions. To
understand the potential of romiplostim to treat CIT, we
have used a mouse model of multicycle CRT-induced
thrombocytopenia to explore romiplostim dose levels and
schedule. As in humans (reviewed in [23]), studies exam-
ining eTPO found an inverse relationship between platelet
counts and eTPO concentrations in mice treated with
CRT. We hypothesized that the period of time immediately
after CRT but before the elevation in eTPO might provide a
therapeutic window during which romiplostim administra-
tion would be effective in enhancing platelet recovery. In
the experiments described here, romiplostim accelerated
platelet recovery compared with CRT alone in most condi-
tions tested, with higher doses administered closer to CRT
providing the greatest benefit. Doses of $100 mg/kg given
Figure 6. Romiplostim mitigated CRT-induced anemia and promoted
earlier reticulocyte recovery. (A) In the example shown, mice were treated
with 10, 30, or 100 mg/kg of romiplostim on day 0 of the third CRT cycle.
Similar results were seen with other administration schedules and cycles of
treatment. Untreated mice were included to show baseline platelet values.
Mice with CRT treatment alone were used as a negative control. Reticulo-
cytes were measured throughout cycle three, as indicated (n 5 5 mice per
group, per time point). Error bars represent the standard error of the mean.
The symbols above the lines indicate days of statistically significant
differences between the following treatment groups and CRT alone:
o 5 100 mg/kg; x 5 30 mg/kg (p ! 0.05, two-way ANOVA with Bonfer-
roni post-hoc test). (B) In the example shown, mice were treated with 10,
30, or 100 mg/kg of romiplostim on day 0 of the third CRT cycle. Similar
results were seen with other administration schedules and cycles of treat-
ment. Untreated mice were included to show baseline platelet values. Mice
with CRT treatment alone were used as a negative control. Hemoglobin
was measured throughout cycle three, as indicated (n 5 5 mice per group,
per time point). Error bars represent the standard error of the mean. The
symbols above the lines indicate days of statistically significant differences
between the following treatment groups and CRT alone: o 5 100 mg/kg;
x5 30 mg/kg; þ5 10 mg/kg (p! 0.05, two-way ANOVAwith Bonferroni
post-hoc test). Hb 5 hemoglobin; Retics 5 reticulocytes. (Color illustra-
tion of figure appears online.)
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platelet nadir in both cycle two and cycle three. This finding
is in concordance with prior preclinical experiments in
mice, in which a single TPO dose given close to the timeof total body irradiation resulted in better platelet recovery
[3,6,7].
It is worth noting that in mice treated with higher doses
of romiplostim ($100 mg/kg) administered on day 0 in
cycle three of CRT, we observed that platelet counts
decreased more rapidly than in mice receiving CRT alone.
The reason for this decrease is unknown and warrants
further investigation.
The work described here raises some interesting ques-
tions. For example, treatment with romiplostim early in
the CRT cycle improved platelet recovery. Therefore, it
would be of interest to understand the kinetic effects of
romiplostim on megakaryocytes in the bone marrow after
multicycle CRT. These effects may be similar to the posi-
tive impact of recombinant human thrombopoietin
(rHuTPO) on megakaryocyte numbers in bone marrow,
returning numbers close to normal sooner than controls in
a mouse mitomycin C model of myelosuppression [24].
Though romiplostim shortened the platelet nadir, the full
recovery to baseline levels did not occur until late in the
cycle. It would therefore be interesting to examine whether
additional administration of romiplostim later in the cycle
would be of benefit. Interestingly, a recent report has found
that newly generated platelets from immune thrombocyto-
penia patients that were treated with TPO-receptor agonists
were less prone to apoptosis after the first week than plate-
lets analyzed before treatment [25]. However, this returned
to baseline after 2 weeks. This may be due to direct or in-
direct action of the TPO-receptor agonists on newly gener-
ated platelets to increase prosurvival AKT signaling
downstream of the TPO receptor [25]. Although a potential
direct action of TPO-receptor agonists on platelets could
raise a theoretical concern about platelet activation, TPO-
receptor agonists are generally well tolerated. Increases in
thromboembolic events have been reported in patients,
though the majority of events reported were in patients
with thromboembolic risk factors (reviewed in [26]).
It has been reported that administration of TPO and
PEG-rHuMGDF in patients resulted in the generation of
antibodies that cross-react with the endogenous protein
[18,27]. We also found that mice generated antibodies in
response to romiplostim treatment, likely due to the admin-
istration of a foreign protein (human) to mice (data not
shown). Since romiplostim is a TPO-peptide mimetic fused
to Fc and is not homologous to TPO, these antibodies did
not crossreact or neutralize eTPO (data not shown).
InCRT-treatedmice, romiplostimhad a protective effect on
hemoglobin levels but did not affect other hematopoietic line-
ages. The lack of romiplostim’s effect on reducing the time of
neutropenia is in contrast to that observed with rHuTPO in a
mouse mitomycin C model of myelosuppression [24], though
in this model a positive impact on reducing anemia was also
observed. Positive impacts on platelets and hemoglobin have
also been observed for TPO-mimetic eltrombopag in refrac-
tory aplastic anemia patients [28]. In the same study, the
486 P.L. McElroy et al./ Experimental Hematology 2015;43:479–487researchers also observed an improvement in neutropenia and
concluded that eltrombopag may have stimulated the TPO re-
ceptor on hematopoietic stem cells, though the precise mech-
anism has not been defined. It is unclear whether romiplostim
would have a similar trilineage beneficial effect in aplastic
anemia patients. A positive impact of rHuTPO was observed
on reticulocytes in a total-body irradiation model in rhesus
monkeys, though reticulocyte increases were not seen until af-
ter 7 days [29]. This is similar to our study, in which we
observed an early decrease in reticulocytes in all CRT-
treated mice, with subsequent increases above the CRT-
alone values starting at 12 days and continuing for the latter
part of the cycle.
In summary, in a mouse model of CIT, romiplostim was
effective at accelerating platelet recovery and reducing the
extent of the nadir when dosed in each cycle of CRT tested,
before eTPO concentrations had increased to stimulate an
increase in platelets. Though the authors acknowledge the
limitations of using preclinical models to mimic conditions
occurring in patients, we propose that these data may serve
as the basis to study the effects of romiplostim in reducing
thrombocytopenia in patients receiving high-dose chemo-
therapy and CRT.Acknowledgments
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